The research further showed that IgG and neutralising antibody levels in previously infected participants were significantly higher after one dose than those in fully vaccinated volunteers with no history of infection.Ī second dose did not increase the production of neutralising antibodies in previously infected volunteers. However, even within three weeks of receiving the first dose, 94 per cent of these participants developed IgG antibodies against the virus, and 90 per cent showed evidence of neutralising antibodies, which interfere with the ability of viruses to infect cells.
Three weeks after the second dose, all volunteers with no prior infection generated virus-specific immunoglobulin G (IgG) antibodies - the most common type of antibody found in blood. In the latest study, the researchers compared the effects of one and two shots of Sputnik V on SARS-CoV-2-specific antibody responses in 289 healthcare workers in Argentina. The AstraZeneca vaccine, for example, shows 76 per cent efficacy after a single dose, and the Moderna and Pfizer vaccines may induce sufficient immunity in previously infected individuals after one dose, with no apparent benefit of an additional dose, they said. The researchers noted that evidence from other vaccines offers support for the one-shot approach. "The peer-reviewed data we present provide information for guiding public health decisions in light of the current global health emergency," Gamarnik said. "Due to limited vaccine supply and uneven vaccine distribution in many regions of the world, health authorities urgently need data on the immune response to vaccines to optimize vaccination strategies," said study senior author Andrea Gamarnik of the Fundacion Instituto Leloir-CONICET in Buenos Aires, Argentina.
0 kommentar(er)
